Cargando…
Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study
This cohort study assessed the pancreatic safety of vildagliptin versus other noninsulin antidiabetic drugs (NIADs) based on data from five European electronic health care databases. Patients with type 2 diabetes aged ≥18 years on NIAD treatment were enrolled. Adjusted incidence rate ratios (IRRs) a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458459/ https://www.ncbi.nlm.nih.gov/pubmed/31008361 http://dx.doi.org/10.1002/edm2.52 |
_version_ | 1783410010739441664 |
---|---|
author | Williams, Rachael Kothny, Wolfgang Serban, Carmen Lopez‐Leon, Sandra Schlienger, Raymond |
author_facet | Williams, Rachael Kothny, Wolfgang Serban, Carmen Lopez‐Leon, Sandra Schlienger, Raymond |
author_sort | Williams, Rachael |
collection | PubMed |
description | This cohort study assessed the pancreatic safety of vildagliptin versus other noninsulin antidiabetic drugs (NIADs) based on data from five European electronic health care databases. Patients with type 2 diabetes aged ≥18 years on NIAD treatment were enrolled. Adjusted incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were estimated separately for acute pancreatitis and pancreatic cancer for vildagliptin (± other NIADs) compared with other NIADs using negative binomial regression. Approximately 2.8% of the enrolled patients (n = 738 054) used vildagliptin during the study, with an average follow‐up time of 1.4 years. For acute pancreatitis, adjusted IRRs ranged between 0.89 andt 2.58 with all corresponding 95% CIs crossing 1. For pancreatic cancer adjusted IRRs ranged from 0.56 to 3.64, with the lower limit of 95% CIs >1 in some analyses. Post hoc sensitivity analyses taking latency time into account markedly lowered the risk estimates with corresponding 95% CIs crossing 1. Overall, the results do not suggest an increased pancreatitis risk with vildagliptin, while the observation for pancreatic cancer have to be interpreted carefully as this study was not designed to assess pancreatic cancer and rather be explained by certain underlying limitations including latency ‐time, chance findings and/or bias and confounding. |
format | Online Article Text |
id | pubmed-6458459 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64584592019-04-19 Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study Williams, Rachael Kothny, Wolfgang Serban, Carmen Lopez‐Leon, Sandra Schlienger, Raymond Endocrinol Diabetes Metab Original Articles This cohort study assessed the pancreatic safety of vildagliptin versus other noninsulin antidiabetic drugs (NIADs) based on data from five European electronic health care databases. Patients with type 2 diabetes aged ≥18 years on NIAD treatment were enrolled. Adjusted incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were estimated separately for acute pancreatitis and pancreatic cancer for vildagliptin (± other NIADs) compared with other NIADs using negative binomial regression. Approximately 2.8% of the enrolled patients (n = 738 054) used vildagliptin during the study, with an average follow‐up time of 1.4 years. For acute pancreatitis, adjusted IRRs ranged between 0.89 andt 2.58 with all corresponding 95% CIs crossing 1. For pancreatic cancer adjusted IRRs ranged from 0.56 to 3.64, with the lower limit of 95% CIs >1 in some analyses. Post hoc sensitivity analyses taking latency time into account markedly lowered the risk estimates with corresponding 95% CIs crossing 1. Overall, the results do not suggest an increased pancreatitis risk with vildagliptin, while the observation for pancreatic cancer have to be interpreted carefully as this study was not designed to assess pancreatic cancer and rather be explained by certain underlying limitations including latency ‐time, chance findings and/or bias and confounding. John Wiley and Sons Inc. 2019-01-24 /pmc/articles/PMC6458459/ /pubmed/31008361 http://dx.doi.org/10.1002/edm2.52 Text en © 2018 Crown copyright. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Williams, Rachael Kothny, Wolfgang Serban, Carmen Lopez‐Leon, Sandra Schlienger, Raymond Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study |
title | Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study |
title_full | Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study |
title_fullStr | Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study |
title_full_unstemmed | Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study |
title_short | Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study |
title_sort | pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: a european, noninterventional, postauthorization safety study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458459/ https://www.ncbi.nlm.nih.gov/pubmed/31008361 http://dx.doi.org/10.1002/edm2.52 |
work_keys_str_mv | AT williamsrachael pancreaticsafetyofvildagliptininpatientswithtype2diabetesmellitusaeuropeannoninterventionalpostauthorizationsafetystudy AT kothnywolfgang pancreaticsafetyofvildagliptininpatientswithtype2diabetesmellitusaeuropeannoninterventionalpostauthorizationsafetystudy AT serbancarmen pancreaticsafetyofvildagliptininpatientswithtype2diabetesmellitusaeuropeannoninterventionalpostauthorizationsafetystudy AT lopezleonsandra pancreaticsafetyofvildagliptininpatientswithtype2diabetesmellitusaeuropeannoninterventionalpostauthorizationsafetystudy AT schliengerraymond pancreaticsafetyofvildagliptininpatientswithtype2diabetesmellitusaeuropeannoninterventionalpostauthorizationsafetystudy |